An upcoming case on the patent eligibility of genetically modified seed in India will have far-reaching ramifications, as Archana Shankar and Gitika Suri of Anand & Anand explain.
The 11th annual ChinaBio Partnering Forum global life science partnering event, which will be held on May 8 and 9 in Shanghai, China, is expected to attract more than 1,400 executives from 500-plus life sciences companies spanning an estimated 25 countries.
A recent case in India reveals the various ways in which pharmaceutical patents can be challenged, as Neeti Wilson, Arpita Kulshreshtha and Gitika Suri of Anand and Anand report.
Naoko Munakata was selected in the LSIPR 50 2018 publication for her influence on the life sciences industry. She featured in the government and policy section, as LSIPR reports.
Changyu Shen was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the government and policy section, as LSIPR reports.
Sung Yunmo was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the government and policy section, as LSIPR reports.
Speaking to LSIPR Leena Menghaney, regional head of Médecins Sans Frontières’ Access Campaign in South Asia, explains the importance of a balanced IP policy in fostering healthy generic competition.
Drug companies can take heart from a range of best practices in the battle against counterfeit medicines, as LSIPR finds out.
As innovation in the CRISPR field continues across the world, questions are being asked about the role of regulating such a powerful tool, while discussions around licensing the technology continue, as LSIPR reports.
In India, there are two core areas of the antibody patenting field that are unsettled and need correcting, as Archana Shanker and Nupur Maithani of Anand and Anand explain.